Market Introduction
Gastrointestinal drugs include promotility drugs, antimotility drugs, and drugs for acid-related disorders. The generally used gastrointestinal drugs as a group are considered safe. Gastrointestinal (GI) disease affects the stomach, pancreas, rectum and large intestine, esophagus, small intestine, gallbladder, and liver. The main symptoms of gastrointestinal disorders are indigestion, heartburn, constipation bloating, and so on.
Market Overview and Dynamics
The South and Central America gastrointestinal drugs market is expected to reach US$ 5,632.72 million by 2027 from US$ 4,160.28 million in 2019. The market is anticipated to grow at a CAGR of 4.0% during 2019–2027. The rising prevalence of gastrointestinal (GI) diseases, and increase in development of biologics are the major factors expected to boost the growth of the gastrointestinal drugs market in South and Central America. However, the market is likely to get impacted by the risk factor such as side effects associated with the drugs during the forecast period.
Key Market Segments
In terms of drug class, the acid neutralizers segment accounted for the largest share of the South and Central America gastrointestinal drugs market in 2019. In terms of route of administration, oral segment accounted for the largest share of the South and Central America gastrointestinal drugs market in 2019. In terms of application, the inflammatory ulcerative colitis segment accounted for the largest share of the South and Central America gastrointestinal drugs market in 2019. In terms of distribution channel, the retail pharmacies segment accounted for the largest share of the South and Central America gastrointestinal drugs market in 2019.
Major Sources and Companies Listed
Several major primary and secondary sources associated with the South and Central America gastrointestinal drugs market report are the World Health Organization (WHO), InterAmerican Heart Foundation (FIC), Brazilian Health Regulatory Agency, International Foundation for Gastrointestinal Disorders, and others.
Reasons to buy report
- It provides understanding of the South and Central America, gastrointestinal drugs market landscape and identifies gastrointestinal drugs market segments that are most likely to guarantee a strong return.
- It guides stay ahead of the race by comprehending the ever-changing competitive landscape for the South and Central America gastrointestinal drugs market.
- It helps efficiently plan merger and acquisition, and partnership deals in the gastrointestinal drugs market by identifying market segments with the most promising probable sales
- It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of gastrointestinal drugs market performance of various segments pertaining to the South and Central America gastrointestinal drugs market.
- It provides gastrointestinal drugs market revenue forecast of the market based on various segments for the period from 2019 to 2027.
SOUTH AND CENTRAL AMERICA GASTROINTESTINAL DRUGS MARKET SEGMENTATION
By Drug Class
- Acid Neutralizers
- Antidiarrheal and Laxatives
- Anti-Inflammatory Drugs
- Antiemetic and Antinauseants
- Biologics
- Others
By Route of Administration
- Oral
- Parenteral
By Application
- Inflammatory Ulcerative Colitis
- Crohn's Disease
- Irritable Bowel Syndrome
- Gastroenteritis
- Celiac Disease
- Others
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Country
- Brazil
- Argentina
- Rest of South and Central America
Company Profiles
- Celltrion Healthcare Co.,Ltd
- GlaxoSmithKline plc
- Johnson and Johnson Services, Inc.
- AstraZeneca
- Takeda Pharmaceutical Company Limited